Who are Nystatin oral suspension's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mycostatin, Liposomal Amphotericin B, Nystatin 10000U/ml, Amphotericin B Deoxycholate, Loceryl NL + Cosmetic varnish, liposomal amphotericin B + paromomycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nystatin-oral-suspension.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Nystatin oral suspension — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nystatin oral suspension (Nystatin oral suspension) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyene macrolide antifungal. Area: Infectious Disease.

marketed Polyene macrolide antifungal Ergosterol Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Nystatin oral suspension (Nystatin oral suspension) — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. Nystatin binds to ergosterol in fungal cell membranes, creating pores that cause leakage and cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nystatin oral suspension TARGET	Nystatin oral suspension	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Polyene macrolide antifungal	Ergosterol
Mycostatin	nystatin	Generic (originally Squibb)	marketed	Polyene Antifungal [EPC]	Ergosterol (fungal cell membrane)	1954-01-01
Liposomal Amphotericin B	Liposomal Amphotericin B	Taiwan Liposome Company	marketed	Polyene antifungal	Ergosterol
Nystatin 10000U/ml	Nystatin 10000U/ml	Riyadh Colleges of Dentistry and Pharmacy	marketed	Polyene macrolide antifungal	Ergosterol
Amphotericin B Deoxycholate	Amphotericin B Deoxycholate	Drugs for Neglected Diseases	marketed	Polyene antifungal	Ergosterol
Loceryl NL + Cosmetic varnish	Loceryl NL + Cosmetic varnish	Galderma R&D	marketed	Morpholine antifungal	Δ14-steroid reductase and Δ8→Δ7-isomerase (ergosterol biosynthesis pathway)
liposomal amphotericin B + paromomycin	liposomal amphotericin B + paromomycin	Drugs for Neglected Diseases	phase 3	Antifungal/antiparasitic combination	Ergosterol (amphotericin B); ribosomal protein synthesis (paromomycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyene macrolide antifungal class)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
Riyadh Colleges of Dentistry and Pharmacy · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nystatin oral suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/nystatin-oral-suspension. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab